Oral proteasome inhibitor with strong preclinical efficacy in myeloma models

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Oral proteasome inhibitor with strong preclinical efficacy in myeloma models ; volume:16 ; number:1 ; day:24 ; month:3 ; year:2016 ; pages:1-10 ; date:12.2016
BMC cancer ; 16, Heft 1 (24.3.2016), 1-10, 12.2016

Creator: Park, Jonghoon

Contributor: Park, Eok
Jung, Cheol-Kyu
Kang, Seung-Wan
Kim, Byung Gyu
Jung, Youngjoo
Kim, Tae Hun
Lim, Ji-Young
Lee, Sung-Eun
Min, Chang-Ki
Won, Kwang-Ai
SpringerLink (Online service)

DOI: 10.1186/s12885-016-2285-2

URN: urn:nbn:de:1111-2016033012880

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:49 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Park, Jonghoon
Park, Eok
Jung, Cheol-Kyu
Kang, Seung-Wan
Kim, Byung Gyu
Jung, Youngjoo
Kim, Tae Hun
Lim, Ji-Young
Lee, Sung-Eun
Min, Chang-Ki
Won, Kwang-Ai
SpringerLink (Online service)

Other Objects (12)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Proteasome inhibition: the dawn of novel therapies in multiple myeloma

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma

Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

$Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses$

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Proteasome inhibition: the dawn of novel therapies in multiple myeloma

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma

Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

$Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses$

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Proteasome inhibition: the dawn of novel therapies in multiple myeloma

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma

Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

$Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses$

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Proteasome inhibition: the dawn of novel therapies in multiple myeloma

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma

Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Proteasome inhibition: the dawn of novel therapies in multiple myeloma

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma

Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Proteasome inhibition: the dawn of novel therapies in multiple myeloma

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma

Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

Related objects

Reset password